Institute of Integrative Medicine, Witten/Herdecke University, Herdecke, Germany.
Institute for Research in Operative Medicine, Witten/Herdecke University, Cologne, Germany.
Complement Ther Med. 2019 Aug;45:136-141. doi: 10.1016/j.ctim.2019.05.026. Epub 2019 Jun 1.
Infantile colic is a common benign disease occurring in early infancy that may have a great impact on family life. In the present study, the effectiveness and safety of the complex homeopathic medicine Enterokind was compared with Simethicone for treating infantile colic.
Current data were drawn from a prospective, multicenter, randomized, open-label, controlled clinical trial that was conducted in 2009 in 3 Russian outpatient clinics. Children received either Enterokind (Chamomilla D6, Cina D6, Colocynthis D6, Lac defloratum D6 and Magnesium chloratum D6) or Simethicone. Data from infants ≤ 6 months with infantile colic are presented here.
The main outcomes assessments were the change of total complaints score (maximum 17 points) and total objective symptoms score (maximum 22 points) after 10 days of treatment.
Data from 125 infants ≤ 6 months with infantile colic were analyzed. The differences in total complaints and objective symptoms scores between baseline and day 10, estimated from the ANCOVA model, were found to be highly significant (p < 0.0001; ITT) in favor of Enterokind, both for complaints (Δ=-2.38; 95% confidence interval (CI): [-2.87; -1.89]) and for objective symptoms (Δ=-2.07; 95% CI: [-2.65; -1.49]). 1 adverse event (AE), vomiting, occurred under Enterokind and was rated to be unlikely related to it; 4 AEs occurred under Simethicone. All AEs were non-serious.
The current study indicates that Enterokind is an effective and safe homeopathic treatment for functional intestinal colic in infants ≤ 6 months.
婴儿绞痛是一种常见的婴儿期良性疾病,可能对家庭生活产生重大影响。本研究比较了复方顺势疗法药物 Enterokind 与西甲硅油治疗婴儿绞痛的疗效和安全性。
目前的数据来自于 2009 年在俄罗斯 3 家门诊诊所进行的一项前瞻性、多中心、随机、开放标签、对照临床试验。患儿接受 Enterokind(Chamomilla D6、Cina D6、Colocynthis D6、Lac defloratum D6 和 Magnesium chloratum D6)或西甲硅油治疗。此处呈现的是婴儿绞痛的 ≤ 6 个月婴儿的数据。
主要疗效评估指标为治疗 10 天后总抱怨评分(最高 17 分)和总客观症状评分(最高 22 分)的变化。
对 125 名 ≤ 6 个月的婴儿绞痛患儿的数据进行了分析。从 ANCOVA 模型估计,从基线到第 10 天,总抱怨和客观症状评分的差异具有高度显著性(p<0.0001;ITT),Enterokind 均有优势,抱怨方面(Δ=-2.38;95%置信区间(CI):[-2.87;-1.89])和客观症状方面(Δ=-2.07;95%CI:[-2.65;-1.49])。Enterokind 组发生 1 例不良事件(AE),呕吐,被评为与药物不太可能相关;西甲硅油组发生 4 例 AE。所有 AE 均为非严重事件。
本研究表明,Enterokind 是治疗 ≤ 6 个月婴儿功能性肠绞痛的一种有效且安全的顺势疗法药物。